Shattuck Labs STTK 深 沪
等待开盘 09-10 09:30:00 美东时间
2.01
+0.130
+6.91%
华盛通- 最 高2.04
- 今 开1.90
- 成交量 143.59万股
- 最 低 1.74
- 昨 收 1.88
- 总市值 9628.54万
- 52周最高 3.95
- 市盈率 静 --
- 换手率 3.00%
- 52周最低 0.6922
- 委 比 18.52%
- 总股本 4790.32万
- 历史最高 60.516
- 量 比 0.32
- 振 幅 15.96%
- 历史最低 0.6922
- 每 手 1
- 风险率 0.69%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Wedbush Initiates Coverage On Shattuck Labs with Outperform Rating, Announces Price Target of $4
Wedbush analyst David Nierengarten initiates coverage on Shattuck Labs (NASDAQ:STTK) with a Outperform rating and announces Price Target of $4.
09-08 21:07
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Pelthos Therapeutics (AMEX:PTHS) stock increased by 25.9% to $28.27 du...
09-04 01:06
Shattuck Labs Closes $103M Private Placement Deal
Shattuck Labs ( ($STTK) ) has issued an update. On August 26, 2025, Shattuck La...
08-26 18:57
Shattuck Labs Announces Closing of up to $103 Million Private Placement and Appointments to Board of Directors
Shattuck Labs announced the closing of a $103 million private placement, led by OrbiMed, to advance SL-325 through Phase 2 trials for IBD and autoimmune diseases. The funds, assuming full warrant exercise, will support operations into 2029. New Board members, Dr. Dan Baker and Dr. Mona Ashiya, join with extensive industry expertise, while outgoing directors Carrie Brownstein, M.D., Michael Lee, Tyler Brous, and Kate Sasser, Ph.D., step down. SL-3...
08-26 10:30
Shattuck Labs Announces IND for SL-325 Is in Effect for the Treatment of Inflammatory Bowel Disease
Shattuck Labs received U.S. FDA approval for its IND application for SL-325, a potential first-in-class DR3 antagonist antibody targeting inflammatory bowel disease (IBD) and other inflammatory diseases. The Phase 1 clinical trial in healthy volunteers is expected to begin dosing in Q3 2025, with enrollment completing by Q2 2026. The trial will evaluate safety, tolerability, and pharmacokinetics to inform future Phase 2 trials. Shattuck's current...
08-21 14:17
美股大行评级 | 潜在涨幅仍有782.74%！Passage BIO遭Canaccord Genuity下调目标价至67美元，维持"买入"评级
今日重点评级关注：Northland Capital Markets：维持BrainsWay"跑赢大市"评级，目标价从15美元升至19美元；Lake Street：维持Hyperfine"买入"评级，目标价从1.5美元升至2美元
08-15 09:30
Leerink Partners Maintains Outperform on Shattuck Labs, Lowers Price Target to $2
Leerink Partners analyst Faisal Khurshid maintains Shattuck Labs (NASDAQ:STTK) with a Outperform and lowers the price target from $4 to $2.
08-15 05:10
Needham Reiterates Hold on Shattuck Labsto Hold
Needham analyst James Ricchiuti reiterates Shattuck Labs (NASDAQ:STTK) from Hold to Hold.
08-14 23:54
Shattuck Labs Q2 EPS $(0.24), Inline
Shattuck Labs (NASDAQ:STTK) reported quarterly losses of $(0.24) per share which met the analyst consensus estimate. This is a 42.86 percent increase over losses of $(0.42) per share from the same period last year.
08-14 18:32
Shattuck Labs Reports Second Quarter 2025 Financial Results and Recent Business Highlights
Shattuck Labs submitted an IND application for SL-325 targeting DR3 receptor, with Phase 1 trial enrollment expected in Q3 2025. Cash balance as of Q2 2025 is approximately $50.5 million, and proceeds from a recent private placement up to $103 million are expected to fund operations into 2029.
08-14 10:30
